Mesoblast limited (ASX:MSB) shares crossed above its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $1.47 and traded as high as $1.45. Mesoblast shares last traded at $1.41, with a volume of 552,583 shares traded.

The firm has a market capitalization of $696.64 million and a price-to-earnings ratio of -7.65. The stock’s fifty day moving average is A$1.47 and its two-hundred day moving average is A$1.41. The company has a quick ratio of 1.64, a current ratio of 1.92 and a debt-to-equity ratio of 15.89.

About Mesoblast (ASX:MSB)

Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease.

Featured Article: The components of the Stochastic Momentum Index

Receive News & Ratings for Mesoblast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast and related companies with MarketBeat.com's FREE daily email newsletter.